Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of PS-341 for Patients With High-Risk, Newly Diagnosed Multiple Myeloma

NCT00075881 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00075881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00075881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of PS-341 for Patients With High-Risk, Newly Diagnosed Multiple Myeloma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2004
Completion date
October 31, 2012
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage i multiple myeloma, stage ii multiple myeloma, stage iii multiple myeloma